Creatv Bio's LifeTracDx® Blood Test Utilized as Exploratory Biomarker in CytoDyn's Phase 2 Study in Patients with Relapsed/Refractory Metastatic Colorectal Cancer [Yahoo! Finance]
CYTODYN INC (CYDY)
NASDAQ:AMEX Investor Relations:
ir.cytodyn.com
Company Research
Source: Yahoo! Finance
MONMOUTH JUNCTION, N.J. March 3, 2026 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv") has announced the initiation of a collaboration with CytoDyn Inc. of Vancouver, Washington ("CytoDyn") to provide its' LifeTracDx ® liquid biopsy test to support a Phase 2 study evaluating CytoDyn's leronlimab in combination with TAS-102 and Bevacizumab in previously treated patients with relapsed/refractory metastatic Colorectal Cancer (mCRC). CreatvBio (PRNewsfoto/Creatv MicroTech, Inc.) CytoDyn's Phase 2 study in mCRC ( NCT06699836 ), now underway, is enrolling 60 participants who will be tested with the LifeTracDx ® blood test at multiple-time points over the course of the trial. Collected under the study protocol as an exploratory biomarker, Creatv Bio's LifeTracDx ® Blood Test will be used to evaluate numeric increases in PD-L1 expression across the patient population. The study's primary endpoint is objective response rate (ORR), defined as the proportion of pa
Show less
Read more
Impact Snapshot
Event Time:
CYDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYDY alerts
High impacting CYTODYN INC news events
Weekly update
A roundup of the hottest topics
CYDY
News
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab [Yahoo! Finance]Yahoo! Finance
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of LeronlimabGlobeNewswire
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology ConferenceGlobeNewswire
- Former West Coast biotech CEO imprisoned for pocketing millions [Yahoo! Finance]Yahoo! Finance
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast CancerGlobeNewswire
CYDY
Sec Filings
- 3/5/26 - Form 8-K
- 1/9/26 - Form 424B3
- 1/9/26 - Form 10-Q
- CYDY's page on the SEC website